Stockscreener 앱 받기
4.635
2.01%
-0.085
Agenus Inc 주식(AGEN)의 최신 뉴스
Agenus (AGEN) presents new phase 1b clinical data on BOT/BAL combination for MSS mCRC - MSN
Director Harrison of AGENUS INC (AGEN) granted 9,228 shares as board fees - Stock Titan
Agenus (AGEN) price target increased by 25.68% to 15.81 - MSN
Technical Analysis: Should you avoid Agenus Inc stock right nowQuarterly Investment Review & Growth-Oriented Investment Plans - baoquankhu1.vn
Armen of Agenus (NASDAQ: AGEN) takes salary in stock - Stock Titan
New Phase II Data on BOT/BAL Combination in Gastroesophageal Cancer at AACR 2026Agenus - Oncodaily
Agenus receives $20M payment under Zydus Life Sciences collaboration - MSN
Buybacks Report: How sensitive is Agenus Inc to inflation2026 Sector Moves & AI Based Trade Execution Alerts - baoquankhu1.vn
Setup Watch: Can Agenus Inc deliver consistent EPS growth2026 Biggest Moves & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Weekly Earnings: Should you avoid Agenus Inc stock right nowPortfolio Performance Report & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Everything Important About Agenus (AGEN) Receiving a Strong Buy Rating Upgrade - Bitget
Agenus unveils Phase II data for BOT BAL and MiNK iNKT therapy in PD-1 refractory cancer - Traders Union
Can Agenus (AGEN) Run Higher on Rising Earnings Estimates? - Yahoo Finance
Agenus Announces Data from Phase II Study of BOT+BAL in Combinati - The National Law Review
All You Need to Know About Agenus (AGEN) Rating Upgrade to Strong Buy - Yahoo Finance
Why Agenus (AGEN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Has Agenus (AGEN) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Phase 3 BATTMAN Trial Launches BOT/BAL in MSS or pMMR Metastatic Colorectal Cancer - Oncodaily
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 - The AI Journal
HC Wainwright Analysts Boost Earnings Estimates for Agenus - MarketBeat
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer - 뉴스와이어
Has Agenus (AGEN) Surpassed Other Healthcare Stocks So Far This Year? - Bitget
Agenus Inc. (AGEN) stock price, news, quote and history - Yahoo Finance UK
Agenus (NASDAQ: AGEN) director awarded 2,448 Deferred Stock Units as board pay - Stock Titan
Agenus Inc. Initiates Landmark Phase 3 BATTMAN Trial In MSS Metastatic Colorectal Cancer - BioPharma APAC
Portfolio Update: Is Agenus Inc benefiting from interest rate changes2026 Final Week & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Agenus begins phase 3 trial for colorectal cancer treatment By Investing.com - Investing.com South Africa
Agenus Enrolls First Patient in Phase 3 BATTMAN Trial for MSS/pMMR Metastatic Colorectal Cancer - Oncodaily
Agenus (AGEN) Launches Global Phase 3 Trial for Innovative Cance - GuruFocus
Agenus (AGEN) Launches Global Phase 3 Trial for Innovative Cancer Treatment - GuruFocus
Agenus Inc Announces First Patient Enrolled In Global Phase 3 BATTMAN Trial Of BOT Plus BAL Immunotherapy Combination In MSS Or PMMR Metastatic Colorectal Cancer - marketscreener.com
Can Agenus' BOT + BAL Immunotherapy Turn Cold Tumors Hot? - RTTNews
Agenus Launches Landmark Global Phase 3 Clinical Trial - Intellectia AI
Agenus begins phase 3 trial for colorectal cancer treatment - Investing.com
Agenus AGM: Bot/Bal Combo Targets “Cold” MSS Colorectal Cancer as Phase III BATMAN Trial Launches - MarketBeat
Agenus announced that the first patient has been enrolled in its global Phase III Battman trial. - Bitget
Agenus (NASDAQ:AGEN) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
1.80%
0.64%
자본화:
|
볼륨(24시간):